Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for SJG-136

Email this page to a colleague

« Back to Dashboard

What is the drug development status for SJG-136?

SJG-136 is an investigational drug.

There have been 4 clinical trials for SJG-136. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1^st 2010.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, Lymphoid, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI) and [disabled in preview].

Summary for SJG-136

US Patents	0
International Patents	0
US Patent Applications	240
WIPO Patent Applications	152
Japanese Patent Applications	79
Clinical Trial Progress	Phase 1 (2010-07-01)
Vendors	27

Recent Clinical Trials for SJG-136

Title	Sponsor	Phase
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin	National Cancer Institute (NCI)	Phase 2
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	Phase 1
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	National Cancer Institute (NCI)	Phase 1

See all SJG-136 clinical trials

Clinical Trial Summary for SJG-136

Top disease conditions for SJG-136

Top clinical trial sponsors for SJG-136

See all SJG-136 clinical trials

US Patents for SJG-136

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson

Medtronic

Mallinckrodt

Harvard Business School

Colorcon

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.